

ASX Announcement

Appendix 3Y – Dr John Cullity

4 November 2021 – Race Oncology Limited (“Race”) announces that Non-Executive Chairman, Dr John Cullity, has sold 217,878 shares to raise funds to enable the exercise of 3 million options expiring toward the end of November via his investment vehicles BioSynergy Partners Pty Ltd and Craganorig Holdings, LLC at the exercise value of \$710k. The shares have been placed with a long-term shareholder via an on-market crossing.

Dr John Cullity commented, *“I am delighted to be placing these shares in the hands of a long-term Race investor and am grateful for the support. The funding generated through the option exercise, expected to take place later in the month, extends Race’s cash runway and will be allocated to furthering the robust clinical program for Zantrene.”*

An Appendix 3Y, Change of Director's Interest notice follows this announcement.

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene®.

Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers. The Company also has compelling clinical data for the use of Zantrene as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), breast and ovarian cancers and is investigating its use in these areas.

Race is pursuing outsized commercial returns for shareholders via its ‘Three Pillar’ strategy for the clinical development of Zantrene.

Learn more at www.raceoncology.com.

Release authorised by:

Phil Lynch, CEO/MD on behalf
of the Race Board of Directors
phillip.lynch@raceoncology.com

Media contact:

Jane Lowe
+61 411 117 774
jane.lowe@irdepartment.com.au

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Race Oncology Limited
ABN	61 149 318 749

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr John Cullity
Date of last notice	3 September 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	1. Craganorig Holdings, LLC – director related entity 2. Biosynergy Partners Pty Ltd – director related entity
Date of change	4 November 2021
No. of securities held prior to change	1. 2,000,000 Options exercisable at \$0.23, expiring 27/11/2021. 2. 5,620,072 Ordinary Shares 1,000,000 Options exercisable at \$0.25, expiring 25/11/2021 189,394 Options exercisable at \$4.50, expiring 16/5/2022
Class	Ordinary Shares
Number acquired	Nil
Number disposed	2. 217,878 Ordinary shares
Value/Consideration includes brokerage/gst Note: If consideration is non-cash, provide details and estimated valuation	\$709,999.04

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	1. 2,000,000 Options exercisable at \$0.23, expiring 27/11/2021 2. 5,402,194 Ordinary Shares 1,000,000 Options exercisable at \$0.25, expiring 25/11/2021 189,394 Options exercisable at \$4.50, expiring 16/5/2022
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market crossing of shares to cover the costs to enable the exercise of options toward the end of November.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.